Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor

This article was originally published here

The partnership will discontinue the evaluation of CNP520 in two pivotal phase II/III studies in the Alzheimer’s Prevention Initiative Generation Programme. According to Novartis, an evaluation of unblinded

The post Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply